The use of 2-(heterocyclyl-carbonyl)-chromen-4-one derivatives (I) as kinase signal transduction inhibiting, regulating and/or modulating medicaments is new. Some of the compounds (I) are new. The use of chromenone derivatives of formula (I) or their derivatives, solvates, salts or stereoisomers (including mixtures in all proportions) is claimed in the production of kinase signal transduction inhibiting, regulating and/or modulating medicaments. [Image] R 1>-R 3>H, OH, OA, phenoxy, Ar, OCOA, SO 3H, SO 3A, OSO 3H, OSO 3A, SO 2A, halo, COOH, COOA, CONH 2, NHSO 2A, COA, CHO or SO 2NH 2; or R 1>+R 2>OCH 2O or OCH 2CH 2O; Het : mono- or bicyclic, saturated, unsaturated or aromatic heterocycle containing 1-4 N, O or S heteroatoms, optionally substituted by 1-3 of =O, =S, =NH, halo, A, -(CH 2) o-Ar, -(CH 2) o-cycloalkyl, -(CH 2) o-OH, -(CH 2) o-NH 2, NO 2, CN, -(CH 2) o-COOH, -(CH 2) o-COOA, -(CH 2) o-CONH 2, -(CH 2) o-NHCOA, NHCONH 2, -(CH 2) o-NHSO 2A, CHO, COA', SO 2NH 2and/or S(O) oA; Ar : phenyl, naphthyl or biphenylyl (all optionally substituted by 1-3 of halo, A, OH, OA, NH 2, NO 2, CN, COOH, COOA, CON 2, NHCOA, NHCONH 2, NHSO 2A, CHO, COA, SO 2NH 2or S(O) oA); A : 1-10C alkyl (optionally substituted by 1-7 F); A' : 1-6C alkyl or benzyl; o : 0-2. Independent claims are included for: (a) (I) (including salts etc.) as new compounds, provided that R 1>is other than H or halo; and (b) the preparation of the new compounds (I). ACTIVITY : Cytostatic; ophthalmological; antidiabetic; antiinflammatory; antirheumatic; antiarthritic; antipsoriatic; dermatological; antiallergic; osteopathic; gynecological; vulnerary; immunosuppressive; immunostimulant; anti-HIV; nootropic; neuroprotective; antiarteriosclerotic; cardiant; vasotropic; cerebroprotective. MECHANISM OF ACTION : Tyrosine kinase inhibitor; Raf kinase inhibitor; antioxidant. 6-Hydroxy-2-(3,5-dichloropyrazine-2-carbonyl)-chromen-4-one (Ia) had IC 509.64 MicroM for inhibition of protein kinase B (PKB).